Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Sitagliptin64 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00255 | 35163991 | Molecules | Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A01605 | 34681219 | Pharmaceuticals (Basel) | Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. | 2021 | Details |
| A01980 | 34543583 | Arch Physiol Biochem | Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1/TLR4/NF-κB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease. | 2021 | Details |
| A02751 | 34260003 | Neurochem Res | Resveratrol Protects SH-SY5Y Cells Against Oleic Acid-Induced Glucolipid Metabolic Dysfunction and Cell Injuries Via the Wnt/β-Catenin Signalling Pathway. | 2021 | Details |
| A03195 | 34094026 | Iran J Basic Med Sci | The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease. | 2021 | Details |
| A03840 | 33852508 | Eur J Gastroenterol Hepatol | The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases. | 2022 | Details |
| A03843 | 33851458 | Hepatology | Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge. | 2021 | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | 2021 | Details |
| A05224 | 33333172 | Biochimie | Beneficial and deleterious effects of sitagliptin on a methionine/choline-deficient diet-induced steatohepatitis in rats. | 2020 | Details |
| A06587 | 32819262 | Curr Drug Saf | Efficacy and Cardiovascular Safety of DPP-4 Inhibitors. | 2021 | Details |
| A07268 | 32559768 | Horm Metab Res | Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2020 | Details |
| A10082 | 31496048 | Physiol Rep | Dipeptidyl peptidase-4 inhibitors and aerobic exercise synergistically protect against liver injury in ovariectomized rats. | 2019 | Details |
| A11803 | 30734333 | Hepatology | Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. | 2019 | Details |
| A11810 | 30729549 | Hepatology | Reply. | 2019 | Details |
| A12334 | 30510994 | Cell Mol Gastroenterol Hepatol | Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice. | 2018 | Details |
| A12659 | 30341767 | Hepatology | Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A12942 | 30214535 | Exp Ther Med | Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. | 2018 | Details |
| A13075 | 30149145 | Diabetes Metab | SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. | 2018 | Details |
| A13100 | 30138985 | Zhonghua Yi Xue Za Zhi | [The expression of chemerin and the influence of sitagliptin on its expression in non-alcoholic fatty liver disease rats complicated with prediabetes]. | 2018 | Details |
| A13592 | 29890569 | Clin Mol Hepatol | Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease. | 2018 | Details |
| A14754 | 29254185 | Oncotarget | Hepatoprotective potential of isoquercitrin against type 2 diabetes-induced hepatic injury in rats. | 2017 | Details |
| A15966 | 28635324 | Antioxid Redox Signal | Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis. | 2017 | Details |
| A16192 | 28511152 | Wiad Lek | [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes]. | 2017 | Details |
| A16562 | 28315901 | Med Sci Monit | The Effect of Sitagliptin on Lipid Metabolism of Fatty Liver Mice and Related Mechanisms. | 2017 | Details |
| A16774 | 28185715 | Clin Ther | Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A16815 | 28157387 | Can J Physiol Pharmacol | Trigonelline attenuates hepatic complications and molecular alterations in high-fat high-fructose diet-induced insulin resistance in rats. | 2016 | Details |
| A16899 | 28104990 | World J Gastroenterol | Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. | 2017 | Details |
| A17203 | 27916420 | Biomed Pharmacother | Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress. | 2016 | Details |
| A17347 | 27832040 | Eur J Gastroenterol Hepatol | Short article: A randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease. | 2017 | Details |
| A17740 | 27627981 | Diabetologia | Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. | 2016 | Details |
| A18391 | 27166182 | Oncotarget | Reduced miR-200b and miR-200c expression contributes to abnormal hepatic lipid accumulation by stimulating JUN expression and activating the transcription of srebp1. | 2016 | Details |
| A18412 | 27151177 | J Hepatol | Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. | 2016 | Details |
| A18741 | 26976710 | Endocrinol Nutr | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. | 2016 | Details |
| A19717 | 26397061 | Mol Med Rep | Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice. | 2015 | Details |
| A19739 | 26381272 | Diabetes Metab Res Rev | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. | 2015 | Details |
| A20048 | 26191473 | Springerplus | Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury. | 2015 | Details |
| A21126 | 25526792 | BMJ Open | Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. | 2014 | Details |
| A22000 | 24901133 | Hepatogastroenterology | Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. | 2014 | Details |
| A22765 | 24322742 | Hepatobiliary Pancreat Dis Int | Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. | 2013 | Details |
| A23630 | 23613622 | World J Gastroenterol | Dipeptidyl peptidase-4: a key player in chronic liver disease. | 2013 | Details |
| A23715 | 23544853 | Metab Syndr Relat Disord | Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. | 2013 | Details |
| A23777 | 23489256 | Hepatol Res | Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. | 2013 | Details |
| A24387 | 22949894 | Case Rep Gastroenterol | Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report. | 2012 | Details |
| A24411 | 22927782 | ScientificWorldJournal | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. | 2012 | Details |
| A25118 | 22155853 | Hepatogastroenterology | Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. | 2012 | Details |
| A25267 | 22024083 | Hepatogastroenterology | Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. | 2012 | Details |
| A25499 | 21765869 | Therap Adv Gastroenterol | The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. | 2011 | Details |
| A30713 | 31921324 | Nutr Metab (Lond) | High levels of dietary methionine improves sitagliptin-induced hepatotoxicity by attenuating oxidative stress in hypercholesterolemic rats. | 2020 | Details |
| A30793 | 31768345 | Liver Cancer | Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model. | 2018 | Details |
| A31144 | 31177586 | Hepatol Res | Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. | 2019 | Details |
| A31832 | 29740221 | Hepat Med | Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial. | 2018 | Details |
| A32601 | 28029729 | Hepatol Res | Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis. | 2017 | Details |
| A33927 | 24842243 | Diabetes Res Clin Pract | Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. | 2014 | Details |
| A34690 | 22870790 | Acta Gastroenterol Belg | Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. | 2012 | Details |
| A43475 | 31613385 | Hepatology | Reply. | 2020 | Details |
| A43478 | 31610029 | Hepatology | Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43731 | 31006135 | Hepatology | Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. | 2019 | Details |
| A43995 | 30196651 | Clin Mol Hepatol | Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone? | 2018 | Details |
| A44587 | 28089090 | J Diabetes Complications | Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. | 2016 | Details |
| A44699 | 27689184 | Ultrasound Int Open | Dynamic Change of Focal Fatty Sparing in Non-Alcoholic Fatty Liver Disease after Treatment with Sitagliptin. | 2016 | Details |
| A44975 | 26566312 | J Clin Biochem Nutr | Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. | 2015 | Details |
| A47935 | 28847797 | Circulation | Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. | 2017 | Details |
| A49971 | 35578028 | Inflamm Res | Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague-Dawley rats fed a high-cholesterol diet. | 2022 | Details |
| A50259 | 35451807 | Curr Med Sci | Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. | 2022 | Details |